Knott David M Jr Grows Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Knott David M Jr boosted its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 875.0% during the 1st quarter, Holdings Channel reports. The fund owned 39,000 shares of the company’s stock after buying an additional 35,000 shares during the period. Centessa Pharmaceuticals comprises about 0.9% of Knott David M Jr’s portfolio, making the stock its 26th largest position. Knott David M Jr’s holdings in Centessa Pharmaceuticals were worth $1,549,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Private Advisor Group LLC purchased a new stake in shares of Centessa Pharmaceuticals in the 1st quarter worth approximately $238,000. Y Intercept Hong Kong Ltd boosted its stake in shares of Centessa Pharmaceuticals by 742.3% during the first quarter. Y Intercept Hong Kong Ltd now owns 96,367 shares of the company’s stock valued at $3,828,000 after purchasing an additional 84,926 shares in the last quarter. Pictet Asset Management Holding SA purchased a new position in Centessa Pharmaceuticals during the first quarter valued at approximately $3,849,000. Caitong International Asset Management Co. Ltd purchased a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $80,000. Finally, T. Rowe Price Investment Management Inc. raised its stake in Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after buying an additional 1,516 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CNTA shares. Needham & Company LLC lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Wolfe Research downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday, March 31st. Truist Financial lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a research report on Monday, April 13th. Wells Fargo & Company cut Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Finally, Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Price Performance

Shares of CNTA opened at $40.50 on Friday. The company has a market cap of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $12.74 and a twelve month high of $40.56. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The company has a 50 day moving average of $40.12 and a two-hundred day moving average of $33.64.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.